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During	fall	2008,	an	outbreak	of	hand,	foot,	and	mouth	
disease	(HFMD)	with	onychomadesis	(nail	shedding)	as	a	
common	feature	occurred	in	Finland.	We	identified	an	un-
usual	enterovirus	type,	coxsackievirus	A6	(CVA6),	as	the	
causative	agent.	CVA6	infections	may	be	emerging	as	a	
new	and	major	cause	of	epidemic	HFMD.	
H
and, foot, and mouth disease (HFMD) is a common 
childhood illness characterized by fever and vesicular 
eruptions on hands and feet and in the mouth (Figure 1). It 
is caused by members of the family Picornaviridae in the 
genus Enterovirus. Complications are rare, but pneumonia, 
meningitis, or encephalitis may occur. Outbreaks of HFMD 
have been mainly caused by 2 types of enterovirus A spe-
cies, coxsackievirus (CV) A16 (CVA16) or enterovirus 71 
(1). Some outbreaks have been associated with CVA10, but 
only sporadic cases involving other members of the entero-
virus A species have been reported (2,3).
During fall 2008, a nationwide outbreak of HFMD oc-
curred in daycare centers and schools in Finland, starting in 
August and continuing at least until the end of the year and 
possibly into the following year. From vesicle fluid speci-
mens of hospitalized children, we identified the etiologic 
agent as coxsackievirus A6.
The Study
In August 2008, vesicle fluid specimens were collected 
from 2 children and 1 parent with HFMD at the Central 
Hospital of Seinäjoki, Southern Ostrobothnia. Specimens 
were sent to the Department of Virology, University of 
Turku, for identification of the causative agent. After detec-
tion of CVA6 in these index cases, the virus was also found 
in specimens obtained from the Pirkanmaa Hospital Dis-
trict (Tampere), Turku University Hospital (Turku), Pori 
Central Hospital (Pori), and Central-Ostrobothnia Central 
Hospital (Kokkola) (Table).
Nucleic acids were extracted from specimens by using 
the NucliSens EasyMag automated extractor (bioMèrieux, 
Boxtel, the Netherlands). When the extracts were analyzed 
for enteroviruses by using real-time reverse transcriptase–
PCR (RT-PCR) specific for the 5′ noncoding region (NCR) 
of picornaviruses (4), amplicons with melting points indis-
tinguishable from each other and typical to enteroviruses 
were obtained.
To identify the enterovirus type in the specimens, RT-
PCR, specific for a partial sequence of the viral protein 
1 (VP1) region, was performed by using the COnsensus-
DEgenerate  Hybrid  Oligonucleotide  (CODEHOP)  Prim-
ers  (bioinformatics.weizmann.ac.il/blocks/codehop.html) 
(5). The amplicons were separated by agarose gel electro-
phoresis, purified with the QIAquick PCR Purification Kit 
(QIAGEN, Hilden, Germany), and sequenced in the DNA 
Sequencing Service Laboratory of the Turku Centre for 
Biotechnology. The virus type in the 3 index specimens, 3 
samples of vesicular fluids, and 1 throat swab was success-
fully identified with sequencing and BLAST (www.ncbi.
nlm.gov/BLAST)  analysis  as  CVA6.  Phylogenetic  rela-
tionships of the sequences were examined by using CVA6 
(Gdula strain), CVA16 (G10), and enterovirus 71 (BrCr) 
prototype strains as well as selected clinical CVA6 isolates 
obtained from GenBank. Sequence alignments were gen-
erated with the ClustalW program (www.ebi.ac.uk/clust-
alw), and the phylogenetic tree was computed by using the 
Jukes-Cantor algorithm and the neighbor-joining method. 
Phylogenetic analyses were conducted by using MEGA4 
software (www.megasoftware.net) and the bootstrap con-
sensus tree inferred from 1,000 replicates (6) (Figure 2).
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Figure	1.	Vesicular	eruptions	in	A)	hand,	B)	foot,	and	C)	mouth	of	
a	6.5-year-old	boy	from	Turku,	Finland,	with	coxsackievirus	(CV)	
A6	infection.	Several	of	his	fingernails	shed	2	months	after	the	
pictures	were	taken.	D)	Onychomadesis	in	a	10-year-old	boy	from	
Seinäjoki,	Finland,	2	months	after	hand,	foot	and	mouth	disease	
with	CVA6	infection.	Photographs	courtesy	of	H.	Kujari	(A–C)	and	
M.	Linna	(D).Phylogenetic analysis placed all CVA6 strains from 
the  HFMD  outbreak  in  1  cluster  (97%–100%  identity), 
whereas  the  nucleotide  identities  between  those  isolates 
and CVA6 prototype strains Gdula, CAV16, G-10, and en-
terovirus 71 BrCr were 82.5%–83.2%, 55.6%–56.6%, and 
55.6%–57.3%, respectively. The closest preceding CVA6 
strain was isolated from cerebrospinal fluid in the United 
Kingdom in 2007 and had 92%–94% nucleotide identity 
with the strains described here (7).
To improve the detection of the novel CVA6 strains 
in clinical specimens, we designed specific VP1 primers 
from the aligned sequences. CVA6vp1 reverse primer (5′-
ACTCGCTGTGTGATGAATCG-3′)  and  CVA6vp1  for-
ward primer (5′-CGTCAAAGCGCATGTATGTT-3′) gen-
erated a 199-bp amplicon. First, cDNA was synthesized in 
a 20-μL reaction mixture containing 1 μmol/L CVA6vp1 
reverse primer, 2.5 mmol/L of each dNTP, 20 U Rever-
tAid H Minus M-MuLV reverse transcriptase (Fermentas, 
St. Leon-Rot, Germany), reaction buffer (Fermentas), 4 U 
RiboLock RNase inhibitor (Fermentas), and 5 μL RNA in-
cubated at 42ºC for 1 h. Then, 5 μL of cDNA was added 
to 20 μL of master mixture containing 0.4 μmol/L each of 
the CVA6vp1 primers and Maxima SYBR Green qPCR 
Master Mix (Fermentas). PCR with melting curve analy-
sis was performed in a Rotor-Gene 6000 real-time instru-
ment (Corbett Research, Mortlake, Victoria, Australia) by 
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Table. Laboratory findings in clinical specimens and epidemiologic data for patients with CVA6 infections, Finland, 2008*  
City or place,  
identification 
Sampling 
date  Sex/age, y  Specimen type   Disease or signs 
CVA6-VP1 
RT-PCR  VP1 sequence
5ƍ  NCR 
sequence 
Seinäjoki               
  Fin/Se8717  2008 Aug  M/1.3  Vesicle fluid  HFMD  Pos  CVA6  CVA6 
  Fin/Se8781  2008 Aug  F/34  Vesicle fluid  HFMD  Pos  CVA6  CVA6 
  Fin/Se8841  2008 Aug  M/0.9  Vesicle fluid  HFMD  Pos  CVA6  CVA6 
  Fin/Se8865  2008 Aug  †  Feces  HFMD  Pos  NR  CVA6 
  Fin/Se8913  2008 Sep  M/10  Throat swab  HFMD  Pos  NR  CVA6 
  Fin/Se8925  2008 Sep  M/0.9  Throat swab  HFMD  Pos  NR  CVA6 
  Fin/Se8926  2008 Sep  †  Vesicle fluid  HFMD  Pos  CVA6  CVA6 
  Fin/Se8927  2008 Sep  F/1.3  Throat swab  HFMD  Pos  NR  CVA6 
  Fin/Se8928  2008 Sep  †  Vesicle fluid  HFMD  Pos  CVA6  CVA6 
  Fin/Se8931  2008 Sep  M/0.8  Throat swab  NA  Pos  NR  CVA6 
Turku               
  Fin/Tu8859  2008 Sep  M/5.8  Throat swab  Fever, tonsillitis  Pos  CVA6  CVA6 
  Fin/Tu8866  2008 Sep  M/3.1  Throat swab  HFMD  Pos  NR  CVA6 
  Fin/Tu81027  2008 Oct  M/1.8  Throat swab  HFMD  Pos  NR  CVA6 
  Fin/Tu81042  2008 Oct  M/1.8  Throat swab  Fever, eczema  Pos  NR  CVA6 
  Fin/Tu81038  2008 Oct  F/2.2  Throat swab  Fever, seizure  Pos  NR  CVA6 
  Fin/Tu81274  2008 Nov  M/6.5  Vesicle fluid  HFMD  Pos  ND  CVA6 
  Fin/Tu81309  2008 Dec  F/3.7  Vesicle fluid  HFMD  Pos  ND  CVA6 
  Fin/Tu81321  2008 Dec  F/1.2  Throat swab  HFMD  Pos  ND  NR 
  Fin/Tu963  2009 Jan  M/1.2  Throat swab  HFMD  Pos  ND  CVA6 
  Fin/Tu/IB  2009 Feb  F/5.7  Nail  Recent HFMD  Pos  ND  CVA6 
Pori               
  Fin/Po8959  2008 Oct  M/4.8  Throat  Fever, vomiting  Neg  ND  CVA6 
  Fin/Po81375  2008 Dec  M/0.5  Vesicle fluid  HFMD  Pos  ND  CVA6 
  Fin/Po81376  2008 Dec  †  Throat  HFMD  Pos  ND  CVA6 
  Fin/Po81324  2008 Dec  M/10  Feces  Fever, eczema  Pos  ND  NR 
  Fin/Po81325  2008 Dec  M/10  Feces  Fever, HFMD 
contact 
Pos  ND  NR 
Tampere               
  Fin/Ta8966  2008 Sep  M/3.1  Tracheal aspirate  NA  Pos  NR  CVA6 
  Fin/Ta81145  2008 Sep  M/2.1  Feces  NA  Pos  NR  NR 
  Fin/Ta81074  2008 Oct  M/0.3  Tracheal aspirate  NA  Pos  ND  CVA6 
  Fin/Ta81125  2008 Oct  F/0.7  Vesicle fluid  HFMD  Pos  CVA6  CVA6 
  Fin/Ta81126  2008 Oct  M/0.3  Vesicle fluid  HFMD  Pos  NR  CVA6 
  Fin/Ta81216  2008 Nov  F/2.0  Throat swab  NA  Pos  ND  CVA6 
  Fin/Ta81252  2008 Nov  M/6.1  Throat swab  NA  Pos  ND  CVA6 
Kokkola               
  Fin/Ko937  2009 Jan  M/10  Vesicle fluid  HFMD  Pos  ND  CVA6 
*CVA6, coxsackievirus A6; VP1, virus protein 1; RT-PCR, reverse transcriptase–PCR; NCR, noncoding region; HFMD, hand, foot, and mouth disease; 
pos, positive; neg, negative; NA, not available; ND, not done; NR, no result (VP1 sequencing was attempted without result). 
†Same patient as on the line above. Coxsackievirus	A6,	Finland
using the following cycling conditions: initial denaturation 
at 95ºC for 10 min, 45 cycles at 95ºC for 15 s, 60ºC for 30 
s, and at 72ºC for 45 s, followed by generation of melting 
curve from 72°C to 95°C with temperature increments of 
0.5°C/s. Partial 5′ NCR sequence of the strains in clinical 
specimens was determined as described (4) and compared 
with the known sequences by using BLAST (http://blast.
ncbi.nlm.nih.gov/Blast.cgi).
During autumn 2008, a total of 47 acute-phase speci-
mens, including 12 vesicle fluid samples, 23 throat swabs, 
2 tracheal aspirates, 5 fecal samples, and 5 cerebrospinal 
fluid specimens from 43 patients yielded amplicons with 
similar melting points as the originally identified CVA6 
strains in 5′ NCR RT-PCR. All specimens were subjected to 
the specific CVA6-VP1 real-time RT-PCR, and a positive 
result was obtained for 11 vesicle fluid samples, 14 throat 
swabs, 2 tracheal aspirates, and 4 fecal samples (Table). 
The virus in 1 throat swab was identified as CVA6 from 
the result of 5′ NCR sequencing alone. None of the CVA6-
positive specimens were positive by an RT-PCR assay with 
CVA16- and EV71-specific primers (8). Attempts to culti-
vate the virus from 8 CVA6 RT-PCR-positive specimens 
were unsuccessful, whereas the prototype strain could be 
propagated in rhabdomyosarcoma cells.
Onychomadesis was 1 characteristic feature in patients 
during this HFMD outbreak; parents and clinicians reported 
that their children shed fingernails and/or toenails within 
1–2 months after HFMD (Figure 1). Only a few published 
reports of nail matrix arrest in children with a clinical his-
tory of HFMD exist in the medical literature (9–11). We 
obtained shed nails from 2 siblings who had HFMD 8 weeks 
before the nail shedding. The nail fragments were stored at 
–70°C for a few weeks and treated with proteinase K be-
fore nucleic acid extraction. The extracts were enterovirus 
positive in 5′ NCR RT-PCR. The virus in one of them was 
identified as CVA6 by the specific RT-PCR and yielded a 5′ 
NCR sequence that was similar to the novel CVA6 strains.
Conclusions
Enterovirus  CVA6  was  a  primary  pathogen  associ-
ated with HFMD during a nationwide outbreak in Finland 
in autumn of 2008. HFMD epidemics have primarily been 
associated with CVA16 or enterovirus 71 infections; those 
caused by enterovirus 71 have occurred more frequently 
in Southeast Asia and Australia in recent years (12). Re-
portedly, CVA10 has been found in minor outbreaks; other 
coxsackievirus A types have been found in only sporadic 
cases of HFMD (2,3). In general, CVA6 infections have 
been seldom detected and mostly in association with her-
pangina (13,14). In Finland, CVA6 has been identified only 
on 4 occasions over 8 years during enterovirus surveillance 
from 2000 to 2007 (15).
Although  the  CODEHOP  primers  were  elementary 
for rapid genotyping of the novel CVA6 strains, we identi-
fied more viruses with the designated CVA6-VP1 specific 
primers. Onychomadesis was a hallmark of this HFMD 
outbreak. To our surprise, we detected CVA6 also in a frag-
ment of shed nail. The same virus could have given rise to 
the outbreak in Spain in 2008 (10). Supposedly, virus rep-
lication damages nail matrix and results in temporary nail 
dystrophy. Whether nail matrix arrest is specific to CVA6 
infections remains to be shown. This study demonstrates 
that CVA6, in addition to CVA16 and enterovirus 71, may 
be emerging as a primary cause of HFMD. 
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